Home / Stocks / TAK

Takeda Pharmaceutical Co (TAK, Drugmakers) Stock Valuation & Fair Value

Significantly overvalued

Takeda Pharmaceutical Co (TAK, Drugmakers) trades at a current P/E of 52.6, about 68% above its historical normal valuation, with a forward growth estimate of 33.6% and a PEG of 1.56. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 31.2 on the same blended earnings, the 2026-11-06 close of $21.02 corresponds to about $12.50 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
52.6
Normal P/E
31.2
PEG
1.56
Fwd growth
33.6%
Div yield
2.5%
RSI (14)
68.7
Neutral
Technical context
  • Price $21.02 at the Nov 6 close, 4.5% above the 20-day average ($20.11) and 9.9% above the 50-day ($19.12).
  • RSI (14) at 68.7.
  • 52-week range $13.66 to $21.19: the price is 0.8% below the high and 53.9% above the low.

The Street vs SeerForecast

Wall Street's mean price target for TAK is $23.03 across 3 analysts, 9.5% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-09-19.

Current P/E and rating by weekCurrent P/E moved from 49.0 to 52.9 between 2026-09-18 and 2026-10-30, against a normal P/E of 31.2, with 0 rating changes over 7 recorded weeks.2026-09-18: P/E 49.0, Significantly overvalued, recalculated for the week of 2026-09-192026-09-18: P/E 49.0, Significantly overvalued, recorded live 2026-09-212026-09-25: P/E 48.8, Significantly overvalued, recalculated for the week of 2026-09-262026-09-25: P/E 48.8, Significantly overvalued, recorded live 2026-09-282026-10-02: P/E 46.2, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 46.2, Significantly overvalued, recorded live 2026-10-052026-10-09: P/E 48.5, Significantly overvalued, recalculated for the week of 2026-10-102026-10-09: P/E 48.5, Significantly overvalued, recorded live 2026-10-122026-10-16: P/E 50.9, Significantly overvalued, recalculated for the week of 2026-10-172026-10-16: P/E 50.9, Significantly overvalued, recorded live 2026-10-192026-10-23: P/E 52.4, Significantly overvalued, recalculated for the week of 2026-10-242026-10-23: P/E 52.4, Significantly overvalued, recorded live 2026-10-262026-10-30: P/E 52.9, Significantly overvalued, recalculated for the week of 2026-10-312026-10-30: P/E 52.9, Significantly overvalued, recorded live 2026-11-0240.050.0Sep 18Sep 28Oct 9Oct 20Oct 30Normal P/E 31.2
Significantly overvalued

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 49.0+57%Significantly overvalued (recalculated)
2026-10-03P/E 46.2+48%Significantly overvalued (recalculated)
2026-10-31P/E 52.9+69%Significantly overvalued (recalculated)
2026-11-02P/E 52.9+69%Significantly overvalued ← now
Show all 14 readings
WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 49.0+57%Significantly overvalued (recalculated)
2026-09-21P/E 49.0+57%Significantly overvalued
2026-09-26P/E 48.8+56%Significantly overvalued (recalculated)
2026-09-28P/E 48.8+56%Significantly overvalued
2026-10-03P/E 46.2+48%Significantly overvalued (recalculated)
2026-10-05P/E 46.2+48%Significantly overvalued
2026-10-10P/E 48.5+55%Significantly overvalued (recalculated)
2026-10-12P/E 48.5+55%Significantly overvalued
2026-10-17P/E 50.9+63%Significantly overvalued (recalculated)
2026-10-19P/E 50.9+63%Significantly overvalued
2026-10-24P/E 52.4+68%Significantly overvalued (recalculated)
2026-10-26P/E 52.4+68%Significantly overvalued
2026-10-31P/E 52.9+69%Significantly overvalued (recalculated)
2026-11-02P/E 52.9+69%Significantly overvalued ← now

Frequently asked questions

Is Takeda Pharmaceutical Co stock overvalued?

At a current P/E of 52.6 versus its historical normal P/E of 31.2, Takeda Pharmaceutical Co trades about 68% above its typical valuation, with a PEG of 1.56 on 33.6% forward growth. tickerseer currently rates it significantly overvalued.

What is Takeda Pharmaceutical Co's fair value and PEG?

Takeda Pharmaceutical Co trades at a current P/E of 52.6 against a historical normal P/E of 31.2, a PEG of 1.56, and a forward growth estimate of 33.6%. Priced at its historical normal P/E of 31.2 on the same blended earnings, the 2026-11-06 close of $21.02 corresponds to about $12.50 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Takeda Pharmaceutical Co changed?

tickerseer's rating has been significantly overvalued since 2026-09-19.

What is the analyst price target for Takeda Pharmaceutical Co?

The mean Wall Street price target for Takeda Pharmaceutical Co is $23.03 across 3 analysts, 9.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track TAK free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.